Rapid motility arrest of the Lyme disease spirochete, Borrelia burgdorferi, by vaccine-induced OspA antibodies

OspA Antibodies Rapidly Arrest B. burgdorferi Motility via Single-Cell Mechanisms

Scientists have discovered that certain antibodies produced by Lyme disease vaccines can make the bacteria stop swimming almost immediately. By using high-resolution microscopy, they showed that these antibodies target a specific protein on the bacteria. This causes the bacteria to lose their ability to move. This discovery provides a mechanical explanation for how vaccines prevent the spread of the pathogen from ticks to humans.

The Confounding Problem of Bacterial Clumping

The causative agent of Lyme disease, Borrelia burgdorferi, is a spirochete. This is a corkscrew-shaped bacterium that relies on internal flagella (tail-like structures used for propulsion) to swim through host tissues. To prevent infection, researchers focus on Outer Surface Protein A (OspA). This is a protein on the bacterial surface that serves as a target for vaccines. OspA-specific antibodies can block the transmission of the bacteria from ticks to humans. They often do this by trapping the bacteria within the tick's midgut.

However, the precise mechanism of this blockade has remained unclear. Previous studies used Transwell assays (laboratory setups where bacteria migrate through a porous membrane) to suggest that OspA antibodies might inhibit motility. But these assays suffered from a technical confounder. OspA antibodies frequently induce agglutination (the clumping together of individual cells into large aggregates). In a Transwell unit, it was difficult to tell if the bacteria failed to move because their engines were broken. Or, perhaps they were simply too physically large to fit through the 3-micron pores of the membrane. This ambiguity left a gap in our understanding of whether antibodies act on the cellular machinery or merely through physical obstruction.

Resolving Motility via the Hanging Drop Assay

To isolate the effect of antibodies on individual cell movement, the authors developed a hanging drop assay. This allows for high-resolution, single-cell monitoring. The methodological architecture relies on three key design choices:

1. Physical Isolation: The researchers spotted a microliter of bacteria in a medium containing 2% gelatin onto a coverslip. They then inverted it. This creates a controlled environment that prevents the massive clumping seen in bulk liquid assays.
2. Dual-Channel Fluorescence: The team used two distinct bacterial strains. One expresses mScarlet (a red fluorescent protein) and another expresses GFP (green fluorescent protein). This allows for simultaneous tracking of OspA-positive and OspA-negative cells in the same field of view.
3. Automated Digital Tracking: Using the TrackMate plugin in Fiji, the researchers applied a localized thresholding algorithm (a way to define object boundaries) to mask individual cells. They then mathematically calculated their trajectories.

This setup allowed the authors to bypass the clumping problem. Instead of measuring how many bacteria passed through a filter, they measured the actual kinetic properties of individual organisms. They tracked mean track speed ($\mu$m/s) and the total distance traveled ($\mu$m).

Immediate Kinetic Arrest

The results demonstrate that OspA-specific antibodies effectively paralyze the bacteria within minutes. The paper reports that the human monoclonal antibody (mAb) 221-7 reduced the speed of OspA-positive spirochetes. The speed dropped from a baseline of $1.4 \pm 0.1\ \mu\text{m/s}$ to just $0.5 \pm 0.1\ \mu\text{m/s}$ within five minutes [Figure 1B].

The impact on productive translocation (movement from one place to another) was profound. While the control (OspA-negative) cells traveled roughly $75 \pm 10\ \mu\text{m}$, the 221-7-treated cells covered only $12 \pm 8\ \mu\text{m}$ [Figure 1B]. The authors also tested several human mAbs targeting different epitopes (specific binding sites on a protein). Most caused a measurable decline in motility [Figure 1D].

Crucially, this effect extends to vaccine-derived immunity. The study shows that sera (the liquid component of blood containing antibodies) from mice immunized with an OspA mRNA vaccine reduced spirochete speed and distance. This reduction correlated with the vaccine dose and the level of protection observed in tick challenge models .

This suggests that motility arrest may serve as a correlate of protection (a measurable indicator of vaccine success).

Unresolved Structural Questions

While the kinetic data is clear, the underlying structural cause remains unknown. The authors observed that antibody treatment coincided with the appearance of "alternate morphologies." These include lariats (loop-like structures), rings, and figure-eight configurations .

One hypothesis is that antibodies drive OspA toward the bacterial poles. This might alter membrane fluidity (how easily molecules move within the cell membrane). However, the authors could not experimentally confirm OspA re-localization using fluorescently tagged antibodies [Video 22]. Therefore, the researchers concluded that while the bacteria change shape, looping at the poles is not strictly necessary to inhibit motility.

The Verdict: A New Metric for Vaccine Success

The evidence presented by Bhattacharyya et al. is compelling. By moving from bulk migration assays to single-cell kinetics, they demonstrated that OspA antibodies exert a rapid and sustained inhibitory effect on B. burgdorferi motility.

This finding shifts how we might evaluate Lyme disease vaccines. Rather than relying solely on complex animal models, researchers may use motility arrest in a hanging drop assay as a proxy for vaccine efficacy. The work connects molecular recognition to physiological failure. It proves that in the microscopic world of spirochetes, losing the ability to swim is a critical step in stopping infection.

Figures from the paper